Lumigan, Travatan Statistically, Not Clinically, Superior To Timolol, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan’s Lumigan (bimatoprost) and Alcon’s Travatan (travoprost) demonstrated statistically, but not clinically, significant improvement over timolol in lowering intraocular pressure, FDA concluded in NDA review documents for the two agents.